Harvard Vaccine Team Exposes Potential Dark Side of Reliance on Cellular Immune Protection The Fate of Monkey #798 By Richard Jeffreys January 2002 proved to be a month of mixed blessings for the AIDS vaccine field. A slew of new…
Newly International North American Activist Alliance Gathers in Vancouver "Gathering Strength to Fight" By Mark Baker For the first time ever, NATAF (newly renamed from the National AIDS Treatment Activists Forum to the North American AIDS Treatment Action Forum) took…
On Friday, October 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead's nucleotide analogue reverse transcriptase inhibitor, tenofovir disoproxil fumarate (brand name, Viread). The labeling requested was for the "treatment of HIV-1 infection in combination with…
Reports of Progress Toward Understanding How Some People Appear to Fight Off HIV Identifying "Resistance" Epitopes By Richard Jeffreys In the United States, long-term studies of HIV-infected and high-risk people have mainly involved gay men -- the group most heavily…
Nongovernmental Organization Access Effort Dealt Stealth Blow By Ivy League Development Institute "We observe no apparent correlation between access to antiretroviral treatment, which is uniformly poor across Africa, and patent status, which varies extensively by country and drug." -- Amir Attaran,…
Investigational New Drugs Currently Being Tested In Humans, By Class Nucleoside RTI 3 Non-nucleoside RTI 7 Protease inhibitor 4 Fusion/binding inhibitor 5 Cellular factors inhibitor 4 Other 2 Total 25 Source: Project Inform
Argentina International AIDS Society Conference Snoozer Prompts Systematic Review of Drug Pipeline By Mark Harrington "Underwhelmingly Innovative" The International AIDS Society inaugurated its new program of summer research meetings with a sleeper of a gathering in the southern hemisphere port…
Shudda, Cudda, Wudda: Reevaluating the Treatment Revolution After the Fall By David Barr "Six Years of Lost Data" David Barr revisits the changes to the federal when-to-start recommendations announced earlier this year and urges us to consider both the roots…
The Drug Development Pipeline, 2001 Development Terminated GW420867X/HBY1293 GlaxoSmithKline JAIDS 2000; also summer IAS meeting ALX40-4C Allelix Pharmaceuticals Formulation difficulties, lack of efficacy AMD3100 AnorMed Inc. Cardiac arrhythmias at high doses, lack of efficacy at low PD-178390 Parke-Davis Casualty of…
Model Physician/Patient Pair Are Latest to Feel the Fury of Fragile, Unforgiving Treatment Plan By David Barr "Data now exist which suggest that even HIV-specific immune function may be augmented with prolonged therapy, providing optimism that meaningful immune control might…